Medical Condition

obesity

Total Trials

18

Recruiting Now

18

Trial Phases

Phase 2, EARLY_Phase 1, Phase 1

Obesity research has been transformed by the GLP-1 receptor agonist class (semaglutide, tirzepatide), which achieves 15–22% body weight reduction — approaching surgical outcomes — and reduces cardiovascular events in overweight adults. The pipeline now includes amylin analogs, glucose-dependent insulinotropic polypeptide (GIP) agonists, and oral small molecules targeting appetite regulation.

Active trials investigate next-generation GLP-1 combinations, bimagrumab (anti-ActRII for muscle-sparing weight loss), retatrutide, cagrilintide combinations, and gut microbiome modulators. Trials also study weight regain prevention after GLP-1 discontinuation — an emerging clinical challenge.

Obesity trials typically require a BMI ≥30 or ≥27 with weight-related comorbidities; prior bariatric surgery often excludes participants.

Frequently Asked Questions — obesity Clinical Trials

How many clinical trials are currently recruiting for obesity?

ClinicalMetric currently tracks 18 actively recruiting clinical trials for obesity, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for obesity?

obesity research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a obesity clinical trial?

Eligibility criteria for obesity trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Mayo Clinic 3 trials

National Heart, Lung, and Blood Institute (NHLBI) 1 trial

Kaiser Permanente 1 trial

The Cleveland Clinic 1 trial

Fundació Sant Joan de Déu 1 trial

obesity

Frequently Asked Questions — obesity Clinical Trials

Recruiting Clinical Trials

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Precursors of Binge Eating Disorder in a Clinical Sample of Adolescents With Obesity

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Adapting and Testing a Novel Digital Health Tool (PREVENT) to Improve Health Behavior Counseling and Cardiovascular Health in Rural Primary Care Clinics

Insulin Regulation of Lipolysis and Lipolysis Proteins

Stand up for Your Health With a Sit-stand Desk

Persistent Organic Pollutants and Mechanical Discharge: Limiting the Impact of Bariatric Surgery Through Personalized Adapted Physical Activity

Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs

PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes

Weight Loss Through Mayo Clinic Diet

Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control

Weight Management in Obese Cancer Patients During Curative Active Treatment

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity